Application of hydroxystearic acid palmitate in preparation of medicine for treating systemic lupus erythematosus
By inhibiting Th17 cell differentiation and regulating Th17/Treg cell balance, the problem of major side effects in the treatment of systemic lupus erythematosus has been solved, which significantly reduces disease activity and renal pathological changes, and provides a safe and reliable treatment plan.
Patent Information
- Application Number
- CN202410996125.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-12
AI Technical Summary
The existing treatment methods for systemic lupus erythematosus have problems with high side effects and high toxicity, especially the long-term use of glucocorticoids can cause lipid metabolism disorders and autoimmune damage, and there are major infections and tumors in biological agents and cellular immunotherapy. risk.
By using PAHSA with a purity of ≥95%, inhibiting Th17 cell differentiation, regulating Th17/Treg cell immune balance, reducing the expression of autoantibodies and related inflammatory factors, and exerting the effect of treating systemic lupus erythematosus.
PAHSA significantly downregulates the genes related to systemic lupus erythematosus, regulates the IL-23R/STAT3/Th17 signaling pathway, reduces the expression of autoantibodies and inflammatory factors, alleviates renal pathological changes, and reduces disease activity, solving the toxic side effects of existing treatment methods.
Smart Images

Figure CN118924728A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to application of PAHSA in preparing a medicine for treating systemic lupus erythematosus by inhibiting Th17 cell differentiation. Background Art
[0002] Fatty acid esters of hydroxyl fatty acids (FAHFAs) are a new type of endogenous lipids with biological functions such as anti-diabetes and anti-chronic inflammation discovered in recent years. Palmitic acid hydroxy stearic acid (PAHSA), the most abundant FAHFAs, has been shown to affect both the immune system and β cells. PAHSA can inhibit T cell responses, especially the expression of Th17-related genes (IL-17 and IL-23) and pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, etc.).
[0003] Systemic lupus erythematosus (SLE) is a diffuse connective tissue disease mediated by autoimmune mechanisms, characterized by the presence of multiple autoantibodies in the body, involving multiple organs / tissues such as the skin, kidneys, and blood system. SLE is more common in women of childbearing age. The incidence rate in my country is about 70 / 100,000, and it is increasing year by year. Since the etiology and pathogenesis of SLE are not yet fully understood, it is more heterogeneous than other autoimmune diseases, and the clinical manifestations are diverse and complex, which brings great difficulties to treatment. It has been reported that the imbalance between helper T cells 17 (Th17) and regulatory T cells (Treg) is the basis for the onset of SLE. The proportion of Th17 cells is significantly increased in SLE patients. It upregulates the immune response through its main cytokine IL-17, promotes inflammation, and mediates the onset of SLE. Previous studies have found that Th17 / Treg cell imbalance is involved in the development of inflammation in SLE organs, and metabolic pathways can regulate the differentiation and function of T cells. Therefore, maintaining the immune balance of Th17 / Treg cells can be used as a treatment for SLE.
[0004] Clinicians use a wide range of drugs to treat lupus, including glucocorticoids, antimalarials, nonsteroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, and B-cell-targeted biologics, with hydroxychloroquine being the cornerstone of SLE treatment. Glucocorticoids are first-line treatment for most SLE manifestations, with doses and duration of treatment based on clinical experience and consensus. The choice of immunosuppressive agents for lupus nephritis is based on histopathologic classification. Belimumab, a monoclonal antibody directed against B-lymphocyte stimulator, has been shown to improve musculoskeletal and mucocutaneous manifestations and immunologic parameters of lupus. Hydroxychloroquine or other antimalarials may prevent disease exacerbations, reduce the risk of congenital heart obstruction, and treat prothrombotic tendencies in lupus patients, including antiphospholipid antibodies or elevated proteinuria.
[0005] At present, whether it is traditional glucocorticoids (GCs), immunosuppressants, or monoclonal antibodies and small molecule drugs, there are certain defects and side effects. Long-term or large-scale use of GCs can cause side effects such as water-salt and sugar-lipid metabolism disorders and impaired autoimmune function, inducing a series of adverse reactions such as Cushing's syndrome, infection, atherosclerosis, diabetes, gastrointestinal bleeding, etc. These adverse reactions and complications may even lead to worsening of the patient's condition and death. Although biological agents and cell immunotherapy have the advantages of high specificity, strong effects, and relatively few toxic and side effects, they also have major risks such as infection and tumors. In general, although the anti-inflammatory immunosuppressive therapy based on GCs has certain clinical efficacy, it can also cause lipid metabolism disorders, damage to the body's own immune function and other toxic and side effects. Therefore, it is particularly urgent and important to deeply study the pathogenesis of SLE and develop effective, safe and reliable drugs with clear targets. It is a major scientific problem that needs to be solved urgently. Summary of the invention
[0006] The purpose of the present invention is to address the deficiencies of the prior art and provide an application of PAHSA in the preparation of a drug for treating systemic lupus erythematosus by inhibiting Th17 cell differentiation.
[0007] In order to achieve the above object, the technical solution of the present invention is to provide the use of PAHSA in the preparation of a drug for treating systemic lupus erythematosus.
[0008] Furthermore, PAHSA can be used in the preparation of drugs for the treatment of systemic lupus erythematosus by inhibiting Th17 cell differentiation and regulating Th17 / Treg cell immune balance.
[0009] In the above application, the purity of PAHSA is ≥95%, and the effective dose of PAHSA in mice is 4 mg / (Kgd).
[0010] The beneficial effects of the present invention are:
[0011] PAHSA can significantly downregulate genes related to systemic lupus erythematosus and IL-17, regulate the IL-23R / STAT3 / Th17 signaling pathway, reduce the expression of autoantibodies and related inflammatory factors, alleviate renal pathological changes, thereby reducing the disease activity of SLE mice and exerting its therapeutic effect in SLE. In addition, as a new type of endogenous lipid molecule, PAHSA can solve the problem of large toxic and side effects of existing SLE treatments. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] The present invention is further described below in conjunction with the accompanying drawings and embodiments;
[0013] Figure 1 This is a summary diagram of the application of PAHSA in the treatment of systemic lupus erythematosus by inhibiting Th17 cell differentiation;
[0014] Figure 2 The expression of PAHSA in plasma of SLE patients and healthy controls (A) and serum of lupus mice and normal mice (B) was detected by lipidomics.
[0015] Figure 3 The spleen and lymph node characteristics of MRL / Lpr mice after PAHSA treatment (A), spleen index (B), lymph node index (C), serum anti-ds-DNA (D), ANA (E) expression;
[0016] Figure 4 HE, immunohistochemistry and immunofluorescence detection of IgG expression in mouse kidney pathological sections;
[0017] Figure 5 PCA plot of mouse spleen RNA transcriptome (A) and the number of genes regulated in each group (B);
[0018] Figure 6 Heat map (A) and KEGG pathway map (B) of genes downregulated in PAHSA-treated mice compared with the model group
[0019] Figure 7 The following are the flow cytometry images of Th17 and Treg cells in the spleen of mice after PAHSA treatment (A), the percentage of Th17 cells in the spleen (B), and the percentage of Treg cells in the spleen (C);
[0020] Figure 8 Flow cytometry of Th17 cell differentiation after intervention with different concentrations of PAHSA (A) and percentage of Th17 cell differentiation (B);
[0021] Fig. 9The bar graph (A) and histogram (B) of p-STAT3 and STAT3 protein expression in the spleen of mice after PAHSA treatment, and the expression of p-STAT3, STAT3 (CD), ROR-γt protein (EF) and ROR-γt mRNA (G) in Th17 cells after PAHSA intervention;
[0022] Fig.10 The expression of IL-6 (A), IL-17A (B) and IL-23 (C) in the serum of mice after PAHSA treatment;
[0023] Fig.11 The expression of IL-23R (A, D), IL-6R (B, E), IL-1R1 and TGFβR (C, FG) in Th17 cells after PAHSA intervention. DETAILED DESCRIPTION
[0024] Embodiment 1:
[0025] 1. Experimental Materials
[0026] 1. Reagents: PAHSA, purchased from Cayman Chemical, USA; prednisone acetate (manufacturer: Zhejiang Xianju Pharmaceutical Co., Ltd., specification: 5 mg / tablet, item number: LA21132)
[0027] 2. Animals: 24 MRL / lpr spontaneous lupus mice and 8 MRL / MpJ control mice, 6 weeks old, weighing 25-30 g.
[0028] 3. Cells: Isolation of Naive CD4 T cells from the spleen of MRL / Lpr lupus mice
[0029] 2. Experimental Methods
[0030] 1. Collect 8 mL of anticoagulated blood from SLE patients and healthy controls, let it stand at room temperature for 1 hour, centrifuge it at 3.0 rpm for 15 minutes, and draw the upper plasma for later use.
[0031] 2. Animal grouping and drug intervention: MRL / lpr spontaneous lupus mice, 6 weeks old, weighing 25-30g, were randomly divided into 5 groups according to body weight after feeding for 1 week: model group, western medicine group and PAHSA group, 8 mice in each group, and 8 MRL / MpJ mice were selected as normal control (normal group). The normal group and model group were given single distilled water, and the western medicine group was given prednisone suspension 5mg / (kgd); the above groups were gavaged once a day for 8 weeks; the PAHSA treatment group was gavaged with PAHSA suspension 4mg / (kgd) at the 8th week, once a day, and continued to be administered for two weeks, and gavaged with PAHSA suspension 20mg / (kgd) for three more days before the model was removed, once a day.
[0032] 3. Isolation of Naive CD4 T Cells from the Spleens of MRL / Lpr Lupus Mice
[0033] (1) After killing the mouse, soak it in 75% ethanol for 5 minutes. Take out the spleen in the clean bench and put it into the filter and culture dish. Add 1mL 1640 culture medium and grind it thoroughly. After grinding, put the liquid into a 15mL centrifuge tube and centrifuge it at 300G for 10 minutes. Discard the supernatant. Add 400μL EasySep buffer to resuspend, take 10μL and add it to 1mL monocyte counting solution, pipet it evenly and count it. Then make the volume of cells to 1×10 8 / mL.
[0034] (2) Add an appropriate amount of rat serum to the total volume for blocking, 50 μL / mL. Add the cell suspension to a 14 mL flow tube and add the corresponding amount of Isolation cocktail.
[0035] (3) Add 50 μL / mL of depletion cocktail, pipette gently to mix well, and incubate at room temperature for 2.5 min.
[0036] (4) Vortex the magnetic beads to mix for 30 seconds, add the magnetic beads to the above cell suspension, pipet up and down to mix, and incubate at room temperature for 2.5 minutes.
[0037] (5) Add EasySep buffer, adjust the volume to 5 mL, and pipette up and down 2-3 times to mix.
[0038] (6) Place the above flow tube in the magnetic pole and incubate for 2.5 minutes
[0039] (7) Gently lift the magnetic pole and pour the cell suspension into a new 15 mL centrifuge tube.
[0040] (8) Count the cells again.
[0041] 4. Prepare Th17 and Treg differentiation medium:
[0042] (1) Th17 differentiation medium: RPMI1640 was supplemented with 2 μg / mL anti-CD28, 10 μg / mL anti-IL-4, 10 μg / mL anti-IFN-γ, 100 ng / mL IL-6, 3 ng / mL TGF-β1, 20 ng / mL IL-23, 10 ng / mL IL-1β, 10% FBS, antibiotics, 25 mM glutamine and 55 μM β-mercaptoethanol.
[0043] (2) Treg differentiation medium: RPMI1640 was supplemented with 2 μg / mL anti-CD28, 10 μg / mL anti-IL-4 antibody, 10 μg / mL anti-IFN-γ, 0.1 ng / mL TGF-β1, 20 ng / mL IL-2, 10% FBS, antibiotics, 25 mM glutamine and 55 μM β-mercaptoethanol.
[0044] 5. Lipidomics detection of PAHSA expression in plasma, mouse serum and liver of SLE patients and healthy controls
[0045] (1) Extraction of lipids using the chloroform / methanol method
[0046] Pipette 4mL CHCl3:MeOH solution (1:1, v / v) into a 10mL centrifugal glass tube, add the corresponding amount of plasma / serum, calculate and add the corresponding volume of internal standard mixture according to the ratio, add 2mL of 50mM LiCl solution, vortex and centrifuge for 2.5rcf 11min. Aspirate the lower CHCl3 layer, place it in a new centrifugal glass tube, add 2mL CHCl3 to the upper liquid, vortex and centrifuge for 2.5rcf 11min. Aspirate the lower CHCl3 layer, combine the two organic phases, and place them in a nitrogen blower to completely dry. After drying, pipette 4mL CHCl3:MeOH solution (1:1, v / v), add 2mL of 10mM LiCl solution, repeat the above steps, combine the two organic phases, place them in a nitrogen blower to completely dry, dissolve the above lipid extract in CHCl3:MeOH solution (1:1, v / v), and seal with nitrogen.
[0047] (2) FAHFAs derivatization method
[0048] Resuspend the sample with 200 μL chloroform, vortex for 10 seconds, add the sample to the solid phase microextraction column activated with 5 mL n-hexane, wash the sample tube with 100 μL chloroform, vortex for 10 seconds, add 100 μL washing solution to the solid phase microextraction column, and repeat this step once. First, elute the neutral lipids (such as TAG or CHL and its esters) with 16 mL of 5% ethyl acetate in n-hexane solvent, and then elute FAHFA with 16 mL ethyl acetate. Collect the elution solvent every 2 mL and then dry it under nitrogen flow (8 times). After the eluate is completely dried under nitrogen, add 10 μL ice-cold CH3CN:DMF (4:1) and 10 μL ice-cold 640 mM EDC pure water solution to the tube. Vortex for 10 seconds and place on ice. Add 10 μL 10 mM HOBt MeCN and 10 μL 30 mM AMPP, cover and vortex for 10 seconds. The mixture was incubated at 68°C for 1.5 h. The reaction solvent was washed with 3 mL C / M (1 / 1) and 1.5 mL water, the bottom layer was collected and dried under a nitrogen stream; the residue was resuspended with 80 μL CHCl3 / MeOH (1 / 1, v / v), sealed with nitrogen, and stored at -20°C for testing.
[0049] (3) MDMS-SL lipidomics analysis
[0050] Before injection, the lipid extract was diluted with chloroform / methanol / isopropanol (1:2:4, v / v) solution at different times, and the total lipid concentration was finally less than 50pmol / μL. In mass spectrometry analysis, the first and third poles were used as independent mass analyzers, the mass resolution was set to 0.7Da, and the second quadrupole was used as a collision unit for tandem mass spectrometry. Normally, each complete MS scan uses a signal averaging period of 1min in full scan mode. The tandem mass spectrometer uses a signal averaging period of 2-5min in PIS or NLS scanning mode, and the collision gas pressure is set to 0.1mT. The quantitative values are expressed as absolute concentrations or percentages in the same lipid group. T-test analysis or multivariate analysis methods such as PCA and PLS-DA are used to analyze the lipid characteristics of FAHFAs in lupus liver tissue to mine useful biological information from multidimensional complex data.
[0051] 6. ELISA detection of ANA, ds-DNA, IL-6, IL-17A, and IL-23 levels in mouse serum
[0052] After the experiment, blood was collected from the submandibular vein of the mice and left to stand for 1.5 hours. After the whole blood naturally coagulated and serum was precipitated, the blood sample was centrifuged at 3000r / min for 15 minutes, and then the upper serum was taken, and the expression levels of related antibodies and inflammatory factors were detected by ELISA.
[0053] 7. Spleen and lymph node index
[0054] After the mice were killed, fresh spleens were removed, the surrounding fat was removed, the surface blood stains were blotted dry, photographed, weighed, and the spleen index was calculated using the formula: spleen index = spleen weight (g) / body weight (g) × 100%; bilateral axillary and inguinal lymph nodes were taken, weighed, and the lymph node index was calculated using the formula: lymph node index = lymph node weight (g) / body weight (g) × 100%.
[0055] 8. Pathological changes of kidney
[0056] The right kidney of mice was fixed with 4% paraformaldehyde and used for HE staining to observe the pathological changes of the mouse kidney, immunohistochemistry to detect C3, and immunofluorescence staining to detect IgG deposition.
[0057] 9. Detection of Th17 and Treg cell expression in mouse spleen and in vitro stimulated culture by flow cytometry
[0058] 10. Mouse spleen RNA transcriptome detection
[0059] By extracting mouse spleen RNA, transcriptomics was used to detect the expression of various RNA types in the mouse spleen and their enriched pathways.
[0060] 11. WB was used to detect the expression of STAT3, p-STAT3, IL-23R, IL-6R, IL-1R1, and TGF-βR1 in mouse spleen and Th17 cells cultured in vitro.
[0061] 12. RT-PCR was used to detect the expression of ROR-γt in mouse spleen and Th17 cells cultured in vitro.
[0062] 3. Experimental Results
[0063] 1. Lipidomics results showed that the plasma PAHSA content in SLE patients was significantly lower than that in healthy controls ( Figure 2 A), PAHSA decreased from 41.91±2.71 in healthy people to 30.76±2.29 pmol / mL in SLE patients, a decrease of 27% (P<0.01). Compared with the normal group of mice, the PAHSA content in the serum of lupus mice was significantly reduced ( Figure 2 B). The above results indicate that PAHSA plays a certain role in the pathogenesis of SLE, and the reduction of its content will aggravate the disease activity of SLE.
[0064] 2. ELISA test results showed that PAHSA treatment significantly reduced the spleen and lymph node index of the model group mice ( Figure 3 AD), and inhibited the expression of autoantibodies such as ANA and ds-DNA in mouse serum to a certain extent ( Figure 3 E), showing that PAHSA treatment can significantly reduce disease activity in lupus mice.
[0065] 3. The results of kidney HE staining showed that PAHSA treatment improved the swelling and enlargement of the glomeruli and the infiltration of inflammatory cells in lupus mice, and significantly reduced the deposition of C3 and IgG antigen-antibody complexes in the kidneys, and improved the pathological changes in the kidneys of mice ( Figure 4 ).
[0066] 4. PAHSA treatment can significantly downregulate genes related to systemic lupus erythematosus and effectively downregulate genes related to the IL-17 signaling pathway, further indicating that PAHSA can inhibit related immune inflammation, thereby improving the disease activity of lupus mice and improving the condition of SLE ( Figure 5-6 ).
[0067] 5. PAHSA treatment can significantly reduce the expression level of Th17 in the spleen of lupus mice, thereby reducing the ratio of Th17 / Treg, indicating that PAHSA can improve the immune imbalance of mice ( Figure 7 ); In addition, PAHSA can significantly inhibit Th17 cell differentiation in a dose-dependent manner ( Figure 8 ), further indicating that PAHSA can inhibit related immune responses.
[0068] 6. PAHSA can inhibit the activation of STAT3 signaling pathway in mouse spleen ( Fig. 9 AB); In vitro Th17 cell differentiation experiments showed that PAHSA could significantly inhibit the phosphorylation level of STAT3 protein in Th17 cells ( Fig. 9 CD), and can significantly inhibit the expression of Th17-related transcription factor ROR-γt protein and mRNA (Figure 9E-G), thereby inhibiting Th17 cell differentiation and playing a role in the treatment of SLE.
[0069] 7. PAHSA can inhibit the expression of inflammatory factors downstream of STAT3 / Th17 signal transduction to treat systemic lupus erythematosus; inflammatory factors include IL-6, IL-17A, and IL-23, indicating that PAHSA can inhibit immune inflammation to a certain extent ( Fig.10 ).
[0070] 8. Through the detection and analysis of upstream protein receptors that promote STAT3 / Th17 signal transduction, such as IL-6R, IL-23R, IL-1R1 and TGFβR, it was found that the main target of PAHSA in inhibiting Th17 cell differentiation is IL-23R ( Fig.11 ).
Claims
1. Application of PAHSA in the preparation of drugs for treating systemic lupus erythematosus.
2. The use according to claim 1, characterized in that: PAHSA can be used in the preparation of drugs for the treatment of systemic lupus erythematosus by inhibiting Th17 cell differentiation and regulating the immune balance of Th17 / Treg cells.
